The Aryavarth Express
Bengaluru (Karnataka) [India], January 5: Pharmed, in collaboration with the Indian Orthopaedic Association’s (IOA) Osteoporosis Council, has unveiled the Indian Orthopaedic Association Guidelines for Osteoporosis 2025 at IOACON 2025 held in Guwahati. The guidelines have been published in the Indian Journal of Orthopaedics, the official journal of the IOA, highlighting their scientific credibility and national importance.
The newly released guidelines offer a structured, evidence-based and practical framework for the prevention, early diagnosis and management of osteoporosis. They are designed to support a broad spectrum of healthcare professionals, including orthopaedic surgeons, physicians, specialists, nurses and allied healthcare providers involved in osteoporosis care.
Developed using a robust Delphi consensus methodology, the guidelines reflect the collective expertise of 62 nationally recognised experts in osteoporosis and bone health from across the country. The expert panel included leading clinicians, researchers and academicians such as Dr Ramesh Sen, Dr Shiva Shankar Jha, Dr S. S. Amarnath, Dr Jawahar T. Jethwa, Dr Jai Prakash Tiwari, Dr Chinmoy Das, Dr Srinivas Kambhampati, Dr Murali Poduval, Dr Bharatkumar R. Dave, Dr Ram Chaddha, Dr Karthik Vishwanathan, Dr S. Chandrashekara, Dr Renuka Panchagnula and Dr Sanjay Bhadada, among others.
The guideline development involved six structured rounds of questionnaires, ensuring scientific rigour, transparency and alignment with current clinical evidence. This systematic process is intended to ensure the recommendations remain relevant and adaptable to evolving scientific knowledge over the next five to six years.
Commenting on the release, Dr S. S. Amarnath, Orthopaedic Surgeon and Chairman of the Indian Osteoporosis Council (IOA), said the guidelines were the result of an extensive and collaborative effort involving experts nationwide. He noted that the aim was to produce recommendations that are both scientifically sound and practical for everyday clinical use within the Indian healthcare context.
Dr Srinivas Kambhampati, Orthopaedic Surgeon and Editor-in-Chief of the Indian Journal of Orthopaedics, highlighted the growing burden of osteoporosis in India, particularly with an ageing population. He said the guidelines provide clinicians with a clear, evidence-based and context-specific framework for screening, diagnosis and management, and will serve as a long-term reference for doctors and researchers.
Pharmed, with a legacy spanning over seven decades, continues to focus on evidence-based specialty healthcare solutions to improve patient outcomes. Its association with the guidelines reflects its ongoing commitment to advancing bone and joint health.
Speaking on Pharmed’s role, Dr Jayanta Jana, Senior Executive Vice President – Medical, Regulatory Affairs and Business Alliances, said the company believes progress in bone health begins with strong scientific foundations. He added that supporting the release of the 2025 guidelines reinforces Pharmed’s commitment to evidence-based care, preventive healthcare strategies and sustained engagement with the medical community.
Beyond its therapeutic offerings, Pharmed has also been promoting patient awareness and early detection through the India Bone Health Initiative (IBHI). The initiative conducts nationwide Bone Mineral Density (BMD) screening camps to facilitate early diagnosis and improve access to osteoporosis education, reaching lakhs of people across India.
Through continued collaboration in clinical practice, medical education and patient outreach, Pharmed aims to support a healthcare ecosystem that prioritises bone health, expands awareness and integrates preventive care into routine clinical practice.
